Melatonin for Treatment of Delirium in Critically Ill Adult Patients

The purpose of this study is to determine the feasibility of conducting a randomized controlled trial (RCT) with melatonin for treatment of delirium in critically ill adult patients. From a feasibility perspective, the investigators believe that the proposed design will achieve the minimum enrollment rate necessary to conduct a future RCT on a larger scale.

Inclusion Criteria:Patients aged 18 years or older admitted to the intensive care unit;Anticipated ICU stay > 48 hours;ICDSC score greater than or equal to 4 for a maximum of 48 hours prior to randomization.Exclusion Criteria:Known allergy or hypersensitivity to melatonin or to ingredients in ORA-BLEND SF®;Use of melatonin within 24 hours prior to randomization;Presence of severe structural brain injury (intracranial hemorrhage or traumatic brain injury), severe major neurocognitive disorder, advanced neurodegenerative disease or hepatic encephalopathy;Diagnosis of schizophrenia, bipolar affective disorder, psychotic depression, uremic encephalopathy or alcohol withdrawal;Presence of active seizures, coma, aphasia or severe intellectual disability;Limited short-term vital prognosis;Diagnosis of delirium prior to ICU admission;Pregnancy or breastfeeding;Absolute contraindication to receive enteral medication;Inability to understand or speak English or French;Total blindness.